A comparison of losartan/hydrochlorothiazide vs combination therapy with an angiotensin II receptor antagonist and a calcium channel blocker in hypertensive patients with cardiac hypertrophy

A comparison of losartan/hydrochlorothiazide vs combination therapy with an angiotensin II receptor antagonist and a calcium channel blocker in hypertensive patients with cardiac hypertrophy - Ehime Study -Effect of Anti hypertensive therapy on Regression of Cardiac Hypertrophy (E-SEARCH)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001283

Enrollment

200

Registered

2008-08-01

Start date

2008-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension with cardiac hypertrophy

Interventions

Losartan/hydrochlorothiazide group ARB and CCB combination grou

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1) Hypertensive patients with cardiac hypertrophy, who have been previously treated with monotherapy of an ARB for more than 8 weeks, however, whose blood pressure has not been reached the target defined by the JSH2004 criteria. 2) Men and women aged 20 to 80 years 3) Outpatients 4) Patients who fully understand the study procedures explained to them using explanatory notes and have given written informed consent to participate in the study

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1) Patients with uncontrolled hypertension (diastolic blood pressure>=110mmHg) 2) Patients with secondary hypertension 3) Patients with uncontrolled diabetes (HbA1c>=8.0%) and under treatment with insulin 4) Patients who have stroke, AMI and/or other critical vascular complications that required hospitalization within 6 months prior to the intervention 5) Patients with liver dysfunction [GPT(ALT) over three times the normal value] 6) Patients with renal failure (serum creatinine>=2.0 mg/dL) 7) Patients with a previous history of gout attack or uncontrolled hyperuricemia (>=8.0mg/dL) 8) Patients with cardiac insufficiency (NYHA grade III or IV) 9) Patients with severe malignant cancer or other unfavorable prognostic factors 10) Pregnant or possible pregnant women 11) Patients with a history of hypersensitivity to ingredients of losartan potassium or hydrochlorothiazide 12) Patients with a history of hypersensitivity to thiazide or thiazide-like diuretics 13) Patients with a history of hypersensitivity to ingredients of a calcium channel blocker to be used in the study 14) Patients who are considered not eligible for the study by the attending doctor due to medical reasons

Design outcomes

Primary

Measure	Time frame
Change in left ventricular mass index (LVMI) after 48 weeks of treatment	—

Secondary

Measure	Time frame
-Change in LVMI after 12 and 24 weeks of treatment -Change and % change in systolic and diastolic blood pressure after 12, 24 and 48 weeks of treatment -Change and % in BNP, cystatin C, microalbuminuria, Na/Creatinine ratio, aldosterone, and drug compliance after 12, 24 and 48 weeks of treatment	—

Countries

Japan

Contacts

Public ContactOkura Takafumi

Ehime University Graduate School of Medicine Department of Integrated Medicine and Informatics

okura@m.ehime-u.ac.jp089-960-5302

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026